A case of malignant insulinoma responsive to somatostatin analogs treatment
Abstract Background Insulinoma is a rare tumour representing 1–2% of all pancreatic neoplasms and it is malignant in only 10% of cases. Locoregional invasion or metastases define malignancy, whereas the dimension (> 2 cm), CK19 status, the tumor staging and grading (Ki67 > 2%), and the age of...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-12-01
|
Series: | BMC Endocrine Disorders |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12902-018-0325-4 |
id |
doaj-20e78a3cec044a108a2643ad5dfa258d |
---|---|
record_format |
Article |
spelling |
doaj-20e78a3cec044a108a2643ad5dfa258d2020-11-25T03:58:19ZengBMCBMC Endocrine Disorders1472-68232018-12-011811610.1186/s12902-018-0325-4A case of malignant insulinoma responsive to somatostatin analogs treatmentMariasmeralda Caliri0Valentina Verdiani1Edoardo Mannucci2Vittorio Briganti3Luca Landoni4Alessandro Esposito5Giulia Burato6Carlo Maria Rotella7Massimo Mannelli8Alessandro Peri9Endocrine Unit, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Careggi University HospitalEndocrine Unit, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Careggi University HospitalDiabetology Unit, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Careggi University HospitalDivision of Nuclear Medicine, Careggi University HospitalGeneral and Pancreatic Surgery Department, The Pancreas Institute-University of Verona Hospital TrustGeneral and Pancreatic Surgery Department, The Pancreas Institute-University of Verona Hospital TrustDepartment of Pathology and Diagnostics, University of Verona Hospital TrustDiabetology Unit, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Careggi University HospitalEndocrine Unit, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Careggi University HospitalEndocrine Unit, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Careggi University HospitalAbstract Background Insulinoma is a rare tumour representing 1–2% of all pancreatic neoplasms and it is malignant in only 10% of cases. Locoregional invasion or metastases define malignancy, whereas the dimension (> 2 cm), CK19 status, the tumor staging and grading (Ki67 > 2%), and the age of onset (> 50 years) can be considered elements of suspect. Case presentation We describe the case of a 68-year-old man presenting symptoms compatible with hypoglycemia. The symptoms regressed with food intake. These episodes initially occurred during physical activity, later also during fasting. The fasting test was performed and the laboratory results showed endogenous hyperinsulinemia compatible with insulinoma. The patient appeared responsive to somatostatin analogs and so he was treated with short acting octreotide, obtaining a good control of glycemia. Imaging investigations showed the presence of a lesion of the uncinate pancreatic process of about 4 cm with a high sst2 receptor density. The patient underwent exploratory laparotomy and duodenocephalopancreasectomy after one month. The definitive histological examination revealed an insulinoma (T3N1MO, AGCC VII G1) with a low replicative index (Ki67: 2%). Conclusions This report describes a case of malignant insulinoma responsive to octreotide analogs administered pre-operatively in order to try to prevent hypoglycemia. The response to octreotide analogs is not predictable and should be initially assessed under strict clinical surveillance.http://link.springer.com/article/10.1186/s12902-018-0325-4InsulinomaHypoglycemiaSomatostatin analogsOctreotide |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mariasmeralda Caliri Valentina Verdiani Edoardo Mannucci Vittorio Briganti Luca Landoni Alessandro Esposito Giulia Burato Carlo Maria Rotella Massimo Mannelli Alessandro Peri |
spellingShingle |
Mariasmeralda Caliri Valentina Verdiani Edoardo Mannucci Vittorio Briganti Luca Landoni Alessandro Esposito Giulia Burato Carlo Maria Rotella Massimo Mannelli Alessandro Peri A case of malignant insulinoma responsive to somatostatin analogs treatment BMC Endocrine Disorders Insulinoma Hypoglycemia Somatostatin analogs Octreotide |
author_facet |
Mariasmeralda Caliri Valentina Verdiani Edoardo Mannucci Vittorio Briganti Luca Landoni Alessandro Esposito Giulia Burato Carlo Maria Rotella Massimo Mannelli Alessandro Peri |
author_sort |
Mariasmeralda Caliri |
title |
A case of malignant insulinoma responsive to somatostatin analogs treatment |
title_short |
A case of malignant insulinoma responsive to somatostatin analogs treatment |
title_full |
A case of malignant insulinoma responsive to somatostatin analogs treatment |
title_fullStr |
A case of malignant insulinoma responsive to somatostatin analogs treatment |
title_full_unstemmed |
A case of malignant insulinoma responsive to somatostatin analogs treatment |
title_sort |
case of malignant insulinoma responsive to somatostatin analogs treatment |
publisher |
BMC |
series |
BMC Endocrine Disorders |
issn |
1472-6823 |
publishDate |
2018-12-01 |
description |
Abstract Background Insulinoma is a rare tumour representing 1–2% of all pancreatic neoplasms and it is malignant in only 10% of cases. Locoregional invasion or metastases define malignancy, whereas the dimension (> 2 cm), CK19 status, the tumor staging and grading (Ki67 > 2%), and the age of onset (> 50 years) can be considered elements of suspect. Case presentation We describe the case of a 68-year-old man presenting symptoms compatible with hypoglycemia. The symptoms regressed with food intake. These episodes initially occurred during physical activity, later also during fasting. The fasting test was performed and the laboratory results showed endogenous hyperinsulinemia compatible with insulinoma. The patient appeared responsive to somatostatin analogs and so he was treated with short acting octreotide, obtaining a good control of glycemia. Imaging investigations showed the presence of a lesion of the uncinate pancreatic process of about 4 cm with a high sst2 receptor density. The patient underwent exploratory laparotomy and duodenocephalopancreasectomy after one month. The definitive histological examination revealed an insulinoma (T3N1MO, AGCC VII G1) with a low replicative index (Ki67: 2%). Conclusions This report describes a case of malignant insulinoma responsive to octreotide analogs administered pre-operatively in order to try to prevent hypoglycemia. The response to octreotide analogs is not predictable and should be initially assessed under strict clinical surveillance. |
topic |
Insulinoma Hypoglycemia Somatostatin analogs Octreotide |
url |
http://link.springer.com/article/10.1186/s12902-018-0325-4 |
work_keys_str_mv |
AT mariasmeraldacaliri acaseofmalignantinsulinomaresponsivetosomatostatinanalogstreatment AT valentinaverdiani acaseofmalignantinsulinomaresponsivetosomatostatinanalogstreatment AT edoardomannucci acaseofmalignantinsulinomaresponsivetosomatostatinanalogstreatment AT vittoriobriganti acaseofmalignantinsulinomaresponsivetosomatostatinanalogstreatment AT lucalandoni acaseofmalignantinsulinomaresponsivetosomatostatinanalogstreatment AT alessandroesposito acaseofmalignantinsulinomaresponsivetosomatostatinanalogstreatment AT giuliaburato acaseofmalignantinsulinomaresponsivetosomatostatinanalogstreatment AT carlomariarotella acaseofmalignantinsulinomaresponsivetosomatostatinanalogstreatment AT massimomannelli acaseofmalignantinsulinomaresponsivetosomatostatinanalogstreatment AT alessandroperi acaseofmalignantinsulinomaresponsivetosomatostatinanalogstreatment AT mariasmeraldacaliri caseofmalignantinsulinomaresponsivetosomatostatinanalogstreatment AT valentinaverdiani caseofmalignantinsulinomaresponsivetosomatostatinanalogstreatment AT edoardomannucci caseofmalignantinsulinomaresponsivetosomatostatinanalogstreatment AT vittoriobriganti caseofmalignantinsulinomaresponsivetosomatostatinanalogstreatment AT lucalandoni caseofmalignantinsulinomaresponsivetosomatostatinanalogstreatment AT alessandroesposito caseofmalignantinsulinomaresponsivetosomatostatinanalogstreatment AT giuliaburato caseofmalignantinsulinomaresponsivetosomatostatinanalogstreatment AT carlomariarotella caseofmalignantinsulinomaresponsivetosomatostatinanalogstreatment AT massimomannelli caseofmalignantinsulinomaresponsivetosomatostatinanalogstreatment AT alessandroperi caseofmalignantinsulinomaresponsivetosomatostatinanalogstreatment |
_version_ |
1724457949908172800 |